Retatrutide and Tirzepatide from ₱750 a vial in 25, 50 and 100 packs. Split it with friends or resell it under your own label.From ₱750 a vial: 25, 50 and 100 packs for group buys and resellers.See bulk prices →
Growth hormone axis · Compound
Ipamorelin
Synthetic five-amino-acid growth hormone secretagogue acting on the ghrelin receptor, studied in a phase 2 trial of gut recovery after bowel surgery.
Philippines Peptides editorial deskUpdated Trial data checked 23 September 20266 min read5 sources
The strongest evidence found for Ipamorelin comes from phase 2 human trials, and every finding below carries its evidence level.
What is Ipamorelin
Ipamorelin is a synthetic five-amino-acid growth hormone secretagogue that acts on the ghrelin receptor to release growth hormone from the pituitary. In pigs and rat pituitary cells (Raun et al., 1998), it released growth hormone without raising ACTH or cortisol, unlike the comparison secretagogues, which is why its developers called it selective. Browse the full peptide library for related GH compounds.
In people, the only completed randomised trial identified is a phase 2 placebo-controlled trial in postoperative ileus. In that trial of 117 patients after bowel resection, ipamorelin did not significantly shorten the time to a first tolerated solid meal (median 25.3 against 32.6 hours on placebo). A dose-escalation study in healthy men without a placebo arm found that ipamorelin produced a single growth hormone peak at every dose studied.
How it works
Ghrelin receptor: ipamorelin binds the growth hormone secretagogue receptor, also called the ghrelin receptor, and releases growth hormone from the pituitary. This was shown in animal pharmacology and in a small dose-escalation study in healthy men.
Selectivity: in pigs and rat pituitary cells, ipamorelin released growth hormone without raising ACTH or cortisol, unlike the comparison secretagogues. This selectivity finding comes from animal work.
Ipamorelin in the Philippines
A search of the FDA Philippines registered drug products database on 7 May 2026, listed in the sources below, found no Philippine drug registration for ipamorelin, and a search of the verification portal on 23 September 2026 returned none either.
Benefits studied
Gut recovery after bowel surgery (not shown)
Phase 2 human
A phase 2 placebo-controlled trial of 117 patients after bowel resection found ipamorelin did not significantly shorten the time to a first tolerated solid meal (median 25.3 hours against 32.6 on placebo). Source: Int J Colorectal Dis 2014
Growth hormone release
Small human studies
A dose-escalation study in healthy men, with no placebo arm, found ipamorelin produced a single growth hormone peak at every dose tested. Source: Pharm Res 1999
Selective growth hormone release
Animal and cell
In pigs and rat pituitary cells, ipamorelin released growth hormone without raising ACTH or cortisol, unlike the comparison secretagogues. This is animal and cell evidence only. Source: Eur J Endocrinol 1998
Side effects reported
No human trial in the datasets reports adverse-event rates for Ipamorelin, whose human evidence is limited to phase 2 human (1 completed randomised trial identified). Without controlled data, its safety in people is unknown rather than established.
Regulatory status
FDA Philippines
No registered drug product found on the FDA verification portal.
US FDA
No record foundDrugs@FDA returned no approved or tentatively approved application for this substance. Drugs@FDA does not list investigational products. Separately, the FDA lists it on its page of bulk drug substances for compounding that may present significant safety risks (current as of 22 April 2026); that page concerns compounding, not approval.
European Medicines Agency
No record foundNo row for this substance in the EMA medicines report generated 22 September 2026. That report does not cover national authorisations in EU member states.
How Philippine registration and prescription rules work, and what an unregistered product is under the law, is covered in the regulation hub, and every compound's status side by side is on the status page. This is general information, not legal advice.
Who should not use Ipamorelin
Everything above is research framing. For the material itself, our partner and supplier lists CJC-1295/Ipamorelin 5mg + 5mg at Primara Labs for ₱2,650 (₱2,390 with 10% off), from stock inside the Philippines.
FAQ
What evidence exists for ipamorelin?
The strongest evidence for ipamorelin is rated phase 2 human. One completed phase 2 placebo-controlled trial, in postoperative ileus (n=117), found no significant difference from placebo. It has also been studied for growth hormone release in healthy men, and for growth hormone release, bone growth and gut motility in animals.
What did the ipamorelin phase 2 trial find?
In a phase 2 placebo-controlled trial of 117 patients after bowel resection, ipamorelin did not significantly shorten the time to a first tolerated solid meal: the median was 25.3 hours against 32.6 hours on placebo.
Is ipamorelin selective for growth hormone?
In animal work, yes. In pigs and rat pituitary cells, ipamorelin released growth hormone without raising ACTH or cortisol, unlike the comparison secretagogues, which is why its developers called it selective. That selectivity was measured in animals.
Is ipamorelin registered with FDA Philippines?
No. A search of the FDA Philippines verification portal on 23 September 2026 returned no registered ipamorelin product, as did a search of the registered drug products database on 7 May 2026. In the US, Drugs@FDA returned no approved or tentatively approved application for it, and the European Medicines Agency medicines report has no row for it. See regulatory status by compound.
Where to get Ipamorelin in the Philippines
If the reading is done and the next step is a plan rather than another article, you can build a protocol around your goal at Longevity Manila, which hands off to our partner and supplier, Primara Labs.
The supply index covers what to ask a seller before paying, and why quoted prices vary so widely.
Beck DE, Sweeney WB, McCarter MD; Ipamorelin 201 Study Group. "Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus." Surg Endosc 2014;28(8):2403–2410.
Sinha DK, Balasubramanian A, Tatem AJ, et al. "Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males." Transl Androl Urol 2020;9(Suppl 2):S149–S159.
FDA Philippines drug registry: ipamorelin not listedReference
FDA Philippines Registered Drug Products Database. Verified 2026-05-07: ipamorelin has no Philippine drug registration; somatropin and tesamorelin registered separately for distinct indications.
This page is editorial information for adults researching peptide therapy. It is not medical advice, not a prescription, and not an endorsement of any specific product, supplier, or protocol. Side effects can be serious and individual response varies. Talk to a licensed physician (ideally one with peptide-specific clinical experience) before starting any compound, adjusting a dose, or discontinuing therapy.
In the Philippines, GLP-1 medications are prescription-only under FDA Philippines regulation. Research-grade peptides occupy a regulatory gray area: import for personal research use is generally tolerated, but the Bureau of Customs reserves the right to inspect and detain shipments. Do not import for resale.
